Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2023 Feb 14;151(6):1513–1524. doi: 10.1016/j.jaci.2023.01.028

Figure 2: The CS Component is Correlated With CS Usage and Response to Corticosteroid.

Figure 2:

(A) The two CS components extracted from GSE161805 (pHBEC) and GSE83233 (Bronchial Biopsy) are highly correlated (r = 0.702, p < 0.00001) when expressed in the bronchial epithelial cells of the merged IMSA+SARP dataset. (B) There is a significant difference in CS component expression between patients who had used inhaled CS in the past 12 months and those who had not (Student’s t-test). (C) Comparison of CS component expression between healthy controls, MA-, MA+ and SA patients. Moderate asthma patients with CS have a significantly higher CS component expression level than moderate asthma patients without CS and healthy controls (ANOVA with Tukey post-hoc test). (D) There is no significant difference between the four groups of GSVA expression of the GO term Response to Steroid Hormone (ANOVA, p = 0.506).